Cabrera O, Cuello M, Thörn K, Peerson J, Lindqvist M, Lastre M, González E, Zayas C, Balboa J, Romeo B, Sarandi A, Pérez O

Language: Spanish
References: 18
Page: 19-25
PDF size: 247.89 Kb.

ABSTRACT

Sexually transmitted infections by Herpes Simplex Virus type 2 (HSV-2) are the leading cause of genital ulcers and a major public health problem worldwide. This requires the use of mucosal vaccines, because parenteral vaccines have not been successful. Presently, there are not mucosal adjuvants, for this reason the development of adjuvants is essential for mucosal vaccine strategies. The intranasal (IN) immunizations using HSV-2 glycoprotein D (gD2), coadministered with cochleate (AFCo1+gD2), would be an efficient candidate for future vaccines against HSV2, similar to the gD2 incorporated into AFCo1(AFCo1-gD2). Female C57Bl/6 mice were inoculated with AFCo1-gD2, AFCo1+gD2 or gD2 alone by IN route. The anti gD2 IgG in sera and vaginal fluids and IgG subclasses were measured by ELISA. The lymphoproliferative response in spleen cells, the Th1/Th2 cytokine profile, the protection and the signs of disease against viral challenge were measured. High titers of IgG and IgG2c subclasses were observed in sera of mice that received the gD2 and AFCo1 as adjuvant. No significant differences (p>0.005) were observed in the animals that received AFCo1+gD2 or AFCo1-gD2. a preferential Th1 cytokine profile and 100% of survival after challenge were observed in both groups that received the gD2 and AFCo1, while no survival was observed in the group that only received the gD2. These results showed that the gD2 can be used coadministered with AFCo1 by IN route as a potential vaccine candidate against HSV-2.

REFERENCES

1. 1. McCluskie MJ, Cartier JLM, Patrick AJ, Sajic D, Weeratna RD, Rosenthal KL, et al. Treatment of intravaginal HSV-2 infection in mice: A comparison of CpG oligodeoxynucleotides and resiquimod (R-848). Antiviral Research 2006;69:77-85.

2. O’Farrell N. Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmers. Sex Transm Infect 1999;75:377-84.

3. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol 2003;16(1):96-113.

4. Roizman B, Knipe DM. Herpes simplex viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2001. p. 2399-2459.

5. Stanberry LR. Clinical trials of prophylactic and therapeutic Herpes Simplex Virus vaccine. HERPES 2004;11(Supp 3):161A-169A.

6. Pérez O, Lastre M, Cabrera O, del Campo J, Bracho G, Cuello M, et al. New Vaccines Require Potent Adjuvants like AFPL1 and AFCo1. Scandinavian Journal of Immunology 2007;66:271- 7.

7. Pérez O, Lastre M, Bracho G, del Campo J, Zayas C, Acevedo R, et al. Natural Neisseria derive proteoliposome and cocleate as potent vaccine adjuvants. Pharmacology Online 2006;3:762- 4.

8. Pérez O, Lastre M, Cabrera O, del Campo J, Bracho G, Cuello M, et al. New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand J Immunol 2007;66(2-3):271-7.

9. Del Campo J, Lindqvist M, Cuello M, Bäckström M, Cabrera O, Persson J, et al. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine 2010;28:1193-1200.

10. Harandi AM, Eriksson K, Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 2003;77:953-62.

11. Tengvall S, Josefsson A, Holmgren J, Harandi AM. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice. Journal of Reproductive Immunology 2005;68:53–69.

12. Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, and Harandi AM. Mucosal Administration of CpG Oligodeoxynucleotide Elicits Strong CC and CXC Chemokine Responses in the Vagina and Serves as a Potent Th1-Tilting Adjuvant for Recombinant gD2 Protein Vaccination against Genital Herpes. Journal of Virology 2006;80:5283–91.

13. Cabrera O, Cuello M, Thörn K, Lindqvist M, Lastre M, González E, et al. Influencia de las vías de inmunización mucosales sobre la protección contra Herpes Simple tipo 2 con el AFCo1 como adyuvante. VacciMonitor 2011;20(3):14-20.

14. Cattamanchi A, Posavad CM, Wald A, Baine Y, Moses J, Higgins TJ, et al. Phase I Study of a Herpes Simplex Virus Type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2- seronegative adults by a needle-free injection system. Clinical and Vaccine Immunology 2008;15:1638-43.

15. Harandi AM, Svennerholm B, Holmgren J, Eriksson K. Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J Gen Virol 2001;82:845- 53.

16. Parr MB, Parr EL. The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice. Virology 1999;258(2):282-94.

17. Milligan GN, Bernstein DI. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 1997;229(1):259-68.

18. Lindqvist M, Persson J, Thorn K, and Harandi AM. The Mucosal Adjuvant Effect of a-Galactosylceramide for Induction of Protective Immunity to Sexually Transmitted Viral Infection. J Immunol 2009;182:6435-43.